Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Choosing between SP 500 and multi-asset strategies depends on goals and risk comfort. This intro contrasts outcomes to guide retirement design.
26,826 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
June's consumer price index fell 0.4% month over month, with core prices flat. Gasoline relief helped lower the headl...
Beaten-down brands aren’t a bet on luck—they’re a test of resilience. This piece explores two stocks down right hold ...
Policy experts say what trump's generic drug tariffs could mean for prices and supplies is uncertain, with effects de...
Oil prices rose amid geopolitical tension and supply risks, signaling that prices could back toward the $5 gallon ran...
A Supreme Court ruling blocks Trump’s emergency tariffs, leaving executives silent as refunds, labor concerns, and ma...
Caterpillar dominates with record quarterly revenue fueled by data-center power needs, while Deere delivers a solid b...
Redwire posted a strong revenue beat but a bigger-than-expected loss, triggering a mid-day rally in its stock. This a...
Global energy markets face a widening supply gap as u.s. exporters can’t fill near-term shortages. A pledge to insure...
A fresh federal study reveals stubbornly low starting salaries for graduates in critical fields. Here’s what it means...
Newrez is rolling out TitlePass in its wholesale channel, allowing brokers to waive the lender title insurance on cer...
House Democrats unveiled a pair of bills aimed at banning event contracts on Polymarket US and other platforms. The m...